As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...

The vaccine maker is expanding beyond its COVID-focused offerings.

Pharmaceutical company Moderna says it is scaling down its investments in late-stage vaccine trials amid growing opposition ...

Jan 22 (Reuters) - Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to ...

Moderna Inc.’s chief executive officer said the company doesn’t plan to invest in new late-stage vaccine trials because of ...

In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock ...

Five years ago, a group of high-risk skin cancer patients received a bespoke vaccine. The data is finally in, and the results ...

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update ...

By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...

Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b ...

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...